Pitavastatin
Active ingredient: Pitavastatin Calcium
In short: Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
What is Pitavastatin used for?
Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:
Adults with primary hyperlipidemia.
Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
Pitavastatin dosage
Take pitavastatin tablets orally once daily with or without food at the same time each day.
For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pitavastatin tablets 4 mg daily, prescribe alternative LDL-C-lowering treatment.
Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pitavastatin tablets, and adjust the dosage if necessary.
The recommended dosage range of pitavastatin tablets is 2 mg to 4 mg daily.
The maximum recommended dosage is pitavastatin tablets 4 mg once daily.
The recommended starting dosage for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30 to 59 mL/minute/1.73 m2 and 15 to 29 mL/minute/1.73 m2, respectively) and patients with end-stage renal disease receiving hemodialysis is pitavastatin tablets 1 mg once daily. The maximum recommended dose for these patients is pitavastatin tablets 2 mg once daily .
There are no dosage adjustment recommendations for patients with mild renal impairment.
In patients taking erythromycin, do not exceed pitavastatin tablets 1 mg once daily .
In patients taking rifampin, do not exceed pitavastatin tablets 2 mg once daily .
How to take Pitavastatin β instructions & advice from the label
Myopathy and Rhabdomyolysis
Advise patients that pitavastatin may cause myopathy and rhabdomyolysis. Inform patients that the risk is increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever .
Hepatic Dysfunction
Inform patients that pitavastatin may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice .
Increases in HbA1c and Fasting Serum Glucose Levels
Inform patients that increases in HbA1c and fasting serum glucose levels may occur with pitavastatin. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices .
Pregnancy
Advise pregnant patients and patients who become pregnant of the potential risk to a fetus. β¦
Warnings & precautions
Do not take this medicine if: Pitavastatin tablets are contraindicated in the following conditions:
Concomitant use of cyclosporine .
Acute liver failure or decompensated cirrhosis .
Hypersensitivity to pitavastatin or any excipents in pitavastatin tablets. Hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin tablets .
Pitavastatin may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including pitavastatin.
Risk Factors for Myopathy
Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use of certain drugs (including other lipid-lowering therapies), and higher pitavastatin dosage [see Dosage and Administration (2.2), Drug Interactions (7), and
Use in Specific Populations (8.5, 8.6)]. Dosages of pitavastatin greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. The maximum recommended dose of pitavastatin is 4 mg once daily.
Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis
Pitavastatin is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil . There are pitavastatin dosage restrictions for patients taking erythromycin or rifampin . The following drugs when used concomitantly with pitavastatin may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (> 1 grams/day), fibrates, and colchicine .
Discontinue pitavastatin if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. β¦
Pitavastatin side effects
The following serious adverse reactions are discussed in other sections of the labeling:
Myopathy and Rhabdomyolysis
Immune-Mediated Necrotizing Myopathy
Hepatic Dysfunction
Increases in HbA1c and Fasting Serum Glucose Levels .
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of one drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Adults with Primary Hyperlipidemia
In 10 controlled clinical studies and 4 subsequent open-label extension studies, 3,291 adult patients with primary hyperlipidemia were administered pitavastatin 1 mg to 4 mg daily. The mean continuous exposure of pitavastatin (1 mg to 4 mg) was 36.7 weeks (median 51.1 weeks). The mean age of the patients was 60.9 years (range; 18 years to 89 years) and 52% were females. Approximately 93% of the patients were White, 7% were Asian/Indian, 0.2% were African American and 0.3% were Hispanic and other.
In controlled clinical studies and their open-label extensions, 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg) of pitavastatin-treated patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: elevated creatine phosphokinase (0.6% on 4 mg) and myalgia (0.5% on 4 mg). β¦
Drug interactions
Table 2 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when administered concomitantly with pitavastatin and instructions for preventing or managing drug interactions .
Table 2: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Pitavastatin
Cyclosporine
Clinical Impact: | Cyclosporine significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.
Intervention: | Concomitant use of cyclosporine with pitavastatin is contraindicated .
Gemfibrozil
Clinical Impact: | Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with statins, including pitavastatin.
Intervention: | Avoid concomitant use of gemfibrozil with pitavastatin.
Erythromycin
Clinical Impact: | Erythromycin significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.
Intervention: | In patients taking erythromycin, do not exceed pitavastatin 1 mg once daily .
Rifampin
Clinical Impact: | Rifampin significantly increases peak pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.
Intervention: | In patients taking rifampin, do not exceed pitavastatin 2 mg once daily . β¦
About this medicine
Pitavastatin tablets for oral use is an HMG-CoA reductase inhibitor.
The chemical name for pitavastatin is (+)monocalcium bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate} pentahydrate. The structural formula is:
The molecular formula for pitavastatin is C50H46CaF2N2O8
β5H2O and the molecular weight is 971.06 g/mol. Pitavastatin is odorless and occurs as white to off-white powder. It is freely soluble in tetrahydrofuran, soluble in ethylene glycol, sparingly soluble in dimethyl sulphoxide and in 50 % aqueous acetonitrile, slightly soluble in methanol, very slightly soluble in water and in ethanol (96%), and insoluble in diethyl ether. Pitavastatin is hygroscopic and slightly unstable in light.
Each film-coated tablet of pitavastatin contains 1 mg, 2 mg, or 4 mg of pitavastatin, which is equivalent to 1.045 mg, 2.09 mg, or 4.18 mg, respectively, of pitavastatin calcium and the following inactive ingredients: hypromellose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium aluminometasilicate, and magnesium stearate. β¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7fbfcc0c-9251-456d-a525-e62cfd8abd4b. Read the full official label on DailyMed.
Related medicines
Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Simvastatin Spironolactone